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Abstract
Tuberous sclerosis syndrome (TSC) is an autosomal dominant tumor suppressor gene syndrome affecting multiple organs,
including renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM). LAM is a female-predominant
interstitial lung disease characterized by the progressive cyst formation and respiratory failure, which is also seen in sporadic
patients without TSC. Mutations in TSC1 or TSC2 cause TSC, result in hyperactivation of mammalian target of rapamycin
(mTOR), and are also seen in LAM cells in sporadic LAM. We recently reported that prostaglandin biosynthesis and
cyclooxygenase-2 were deregulated in TSC and LAM. Phospholipase A2 (PLA2) is the rate-limiting enzyme that catalyzes the
conversion of plasma membrane phospholipids into prostaglandins. In this study, we identified upregulation of adipocyte
AdPLA2 (PLA2G16) in LAM nodule cells using publicly available expression data. We showed that the levels of AdPLA2
transcript and protein were higher in LAM lungs compared with control lungs. We then showed that TSC2 negatively
regulates the expression of AdPLA2, and loss of TSC2 is associated with elevated production of prostaglandin E2 (PGE2) and
prostacyclin (PGI2) in cell culture models. Mouse model studies also showed increased expression of AdPLA2 in xenograft
tumors, estrogen-induced lung metastatic lesions of Tsc2 null leiomyoma-derived cells, and spontaneous renal
cystadenomas from Tsc2
+/2 mice. Importantly, rapamycin treatment did not affect the expression of AdPLA2 and the
production of PGE2 by TSC2-deficient mouse embryonic fibroblast (Tsc2
2/2MEFs), rat uterine leiomyoma-derived ELT3 cells,
and LAM patient-associated renal angiomyolipoma-derived ‘‘mesenchymal’’ cells. Furthermore, methyl arachidonyl
fluorophosphate (MAFP), a potent irreversible PLA2 inhibitor, selectively suppressed the growth and induced apoptosis
of TSC2-deficient LAM patient-derived cells relative to TSC2-addback cells. Our findings suggest that AdPLA2 plays an
important role in promoting tumorigenesis and disease progression by modulating the production of prostaglandins and
may serve as a potential therapeutic target in TSC and LAM.
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Introduction
Tuberous sclerosis syndrome (TSC) is an autosomal dominant
tumor suppressor gene syndrome characterized by neurologic
disease, benign tumors in multiple organs, including renal
angiomyolipomas, and pulmonary lymphangioleiomyomatosis
(LAM), which is due to inactivating mutations in either TSC1 or
TSC2 [1]. TSC1 and TSC2, together with TBC1D7, form a
complex and act as a GTPase activating protein (GAP) to reduce
Rheb-GTP levels [2,3]. Loss of either TSC1 or TSC2 leads to
increased Rheb activity which promotes mTORC1 activity and
downstream phosphorylation of S6K, S6 and 4E-BP1, leading to
increased protein synthesis for cellular growth and metabolism [4].
This understanding led to multiple preclinical studies which
demonstrated the effectiveness of rapamycin, an mTORC1
inhibitor, in multiple animal models of TSC [5–11], which led
to rapid clinical translation, and demonstration that rapamycin
has clinical benefit for TSC kidney, lung, and brain tumors [12–
15]. However, these tumors regrow when treatment is discontin-
ued [12–15].
Although most biochemical and signaling effects in cells lacking
TSC1 or TSC2 are thought to occur through activation of
mTORC1, there is evidence that several abnormalities in TSC2-
null cells are independent of mTORC1 [16]. For example, B-Raf
kinase activity is reduced in TSC2-null cells due to high Rheb-
GTP levels, but is independent of mTORC1 [17,18]; and Tsc1 or
Tsc2-null MEFs have a higher percentage of cilium-containing
cells compared to controls, and rapamycin treatment has no effect
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e104809on this observation [19]. Notch activation may also be regulated
by TSC2 in an mTORC1-independent manner [5], although
differing results have also been reported [20]. Recently we
reported that TSC2 negatively regulates COX-2 expression,
prostaglandin production and tumorigenesis in an mTORC1-
insensitive, but mTORC2-dependent manner [10].
Prostaglandins play critical roles in chronic inflammation and
cancer progression [21]. Prostaglandins are products of prosta-
glandin-endoperoxide synthases 1 and 2 (COX-1 and COX-2),
which convert arachidonic acids released from phospholipase A2
(PLA2) -liberated membrane phospholipids, into prostaglandin G2
(PGG2), then PGH2. PGH2 is then converted into different
prostacyclins and thromboxanes by specific isomerases [22,23].
Increased prostaglandin production resulting from PLA2 upregu-
lation may contribute to tumorigenesis via different mechanisms
[23,24].
Despite our previous findings that COX-2 expression and
prostaglandin production were controlled by TSC2 [20], the
relationship between prostaglandin biosynthesis and TSC/LAM
pathogenesis has not been extensively studied. Here, we show
upregulation of adipocyte-specific AdPLA2 expression in LAM
nodule cells relative to non-LAM lungs. We confirmed this finding
by showing that the levels of AdPLA2 transcript and protein were
higher in LAM lungs compared with control lungs. AdPLA2
accumulation is evident in LAM lung nodules and renal
angiomyolipomas. Moreover, we found that TSC2 acts as a
negative regulator of the expression of AdPLA2 and the
production of prostaglandins in vitro and in vivo. Rapamycin
treatment did not affect the expression of AdPLA2 and the
production of PGE2 by TSC2-deficient cells. Finally, we show that
pharmacologic inhibition of PLA2 selectively decreases the growth
and promotes apoptosis of TSC2-deficient patient-derived cells
relative to TSC2-addback cells.
Materials and Methods
Gene expression analysis
Re-analysis of previously published expression array data (GEO
accession number GSE10072 [25,26]; GSE19804 [25,26] and
GSE12027 [27]) were performed using the online tool GEO2R.
Expression levels of PLA2 family members were compared among
LAM cells collected by laser-capture microdissection from LAM
nodules (LAM) and Non-LAM lungs (NL) including lung cancer/
tumor.
Ethics statement
The study protocol was reviewed and approved by the Partners
Human Research Committee (PHRC) of the Brigham and
Women’s Hospital and The Peking Union Medical College in
China. After explanation of the description of the study, the risks
and benefits of the participation, all participants signed a written
consent form.
Human samples
Lung tissue from LAM and control subjects was obtained from
the National Disease Research Interchange (NDRI) and the
Brigham and Women’s Hospital-Pulmonary Division Lung Tissue
Biorepository. Informed consent was obtained for all lung tissues
under Partners approved IRB protocols. Sera from 11 clinical
LAM patients (10 sporadic LAM, one TSC-LAM) were collected
from Peking Union Medical College in China, with informed
consent obtained for research use.
Quantitative RT-PCR
RNA from cultured cells and lung tissues was isolated using
RNeasy Mini Kit (Qiagen). Gene expression was quantified using
One-Step qRT-PCR Kits (Invitrogen) in the Applied Biosystems
Real-Time PCR System and normalized to beta-actin.
Cell culture and reagents
Tsc2
2/2p53
2/2 and Tsc2
+/+p53
2/2 mouse embryonic fibro-
blasts (MEFs) were developed from E10–12.5 embryos collected
from Tsc2
+/2 or Tsc2
+/2p53
2/2 intercrosses [28]. Cell culture
media and supplements were from GIBCO (Frederick, MD). An
immortalized TSC2-deficient human cell line derived from
angiomyolipoma of a LAM patient [29], and its corresponding
TSC2-rescued control cell line has been described previously [30].
Eker rat uterine leiomyoma-derived Tsc2-deficient cells (ELT3)
were developed by Howe et al. [31,32]. Cells were cultured in
DMEM/F12 supplemented with 10% FBS, 0.2 mM hydrocorti-
sone, 0.1 nM triiodothyronine, 0.01 mU/ml vasopressin, 1.6 mM
FeSO4, cholesterol, ITS, 100 ng/ml EGF, 100 mg/ml zeomycin,
and 1% penicillin-streptomycin-amphotericin B (PSA). Experi-
ments were performed in 6–12 replicas for biochemical analyses.
Cells were seeded at a density of 2.5610
5 cells/mL in 6-well plates
in regular growth media for 24 hr, and then treated with inhibitors
or vehicle in serum-free media for 24 hr. Cell-free conditioned
media was collected, and cell lysates were prepared using RIPA
(Boston Bioproducts, Boston, MA) or mPER lysis buffer (Pierce)
supplemented with protease inhibitor cocktail (Roche, Indianap-
olis, IN) and phosphatase inhibitor cocktail (Thermo Scientific,
Waltham, MA). Protein concentration was determined using the
Bradford assay (BioRad Laboratories Inc. Hercules, CA).
Pathway inhibitors
Methyl arachidonyl fluorophosphate (MAFP, 2–10 mM, Cay-
man Chemical), PD98059 (50 mM, Cell Signaling Technology),
PI-103 (5 mM, Tocris), rapamycin (20 nM, Biomols), and Torin 1
(250 nM, Tocris) were used as indicated.
Cell viability assay
Cells were seeded at a density of 5610
4/ml in 96-well plates for
24 hr, and then treated with inhibitors or vehicle for 24 hr. Cell
viability was determined by MTT assay (Sigma). Values are
expressed as mean 6 SEM; n=8/group. *P,0.05; Student’s t-
test.
Animal studies
The Brigham and Women’s Hospital-Children’s Hospital of
Boston Standing Committee on Animals approved all procedures
described according to standards as set forth in The Guide for the
Care and Use of Laboratory Animals. Tsc2
+/2 mice (kindly
provided by Dr. Kwiatkowski) develop renal cystadenomas at high
frequency by 15 months of age [33]. In the current study, 15
months-old Tsc2
+/2 C57Bl6 mice were treated with celecoxib
(0.1% in mouse chow) or vehicle (n=3 mice) for one month, as
described in [10]. Mice were sacrificed and kidneys were
harvested. Xenograft tumor model (n=8 mice/group) was
established as previously described [11]. Animal health was
monitored three days/week during the entire tumor experiments.
The endpoint of the xenograft tumor study was the onset of the
clinical signs of pain/distress including 1) animals are in constant
pain (hunched posture, sluggish movement, vocalization when
handled); 2) bilateral tumors (two subcutaneous tumors/mouse)
have caused inactivity, became ulcerated and/or larger than 15%
of the animal’s body weight (tumor volume ,1,000 mm
3); 3)
AdPLA2 as a Therapeutic Target in TSC and LAM
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were euthanized by carbon dioxide (CO2) inhalation via
compressed gas in response to the onset of the above distress.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded
10 mm-sections using antibodies against AdPLA2. Slides were
deparaffinized and antigen retrieval was performed using sodium
citrate retrieval solution pH 6. Sections were stained by the
immunoperoxidase technique using DAB substrate (Invitrogen)
and counterstaining with hematoxylin.
Immunoblotting analysis
Protein samples were analyzed by SDS-PAGE using 4–12%
NuPAGE Gel (Invitrogen), and transferred to a nitrocellulose
membrane. Immunoblotting was performed by standard methods
using HRP-conjugated secondary antibodies, and chemilumines-
cence using Supersignal West Pico Chemiluminescent substrate
Figure 1. Identification of adipocyte AdPLA2 in LAM associated angiomyolipoma-derived cells and pulmonary LAM nodules using
public expression arrays. (A) Workflow of the expression array analysis of PLA2s using public available gene expression arrays. (B) A heatmap of
the expression of all PLA2s from the re-analysis of previously published expression array data [25,27,34]. (C) The transcript levels of PLA2G16
(phospholipase A2, group XVI, AdPLA2) and PLA24C (phospholipase A2, group IVC, cytosolic, calcium-independent) in LAM lungs (LAM, n=14) and
Non-LAM lungs (NL, n=49). ***P,0.005, Student’s t-test.
doi:10.1371/journal.pone.0104809.g001
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PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e104809Figure 2. Expression of AdPLA2 is upregulated in pulmonary LAM. (A) Real-time RT-PCR analysis of the transcript levels of AdPLA2 in LAM
lungs (LAM) relative to normal lungs (NL). Data show the mean of five sets of independent samples. (B) Immunoblotting analysis of AdPLA2 and
phospho-S6 in lung lysates from pulmonary LAM subjects (LAM lungs, n=6) and from normal lungs (NL, n=3). (C) Immunohistochemical and
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(T202/Y204), Phospho-S6 (S235/236), cleaved caspase 3, cleaved
PARP (Cell Signaling Technology); tuberin (Santa Cruz); smooth
muscle actin (BioGenex); and beta-actin (Sigma).
Quantification of prostaglandin metabolites and VEGF-D
PGE2 and 6-keto-PGF1a were measured using Enzyme Linked
Immuno-Sorbent Assay (ELISA) kits (Cayman Chemical). Levels
of secreted prostaglandins were normalized to protein concentra-
tions and expressed as pg/mg protein. Serum levels of PGE2 and
VEGF-D were quantified using ELISA kits.
Statistical analyses
Statistical analyses were performed using Student’s t-test when
comparing two groups. Results are presented as means 6 SEM.
Results
Identification of adipocyte-specific AdPLA2 upregulation
in pulmonary LAM nodule cells
Our previous studies had identified an estradiol-enhanced
prostaglandin biosynthesis signature in Tsc2-deficient (TSC22)
cells [20]. Since prostaglandin biosynthesis is initiated by PLA2
acting on membrane phospholipids, we examined its expression
using public available expression array data sets from pulmonary
LAM nodule cells collected by laser-capture microdissection (GEO
data set GSE12027) [27], lung cancer/tumor (GEO data set
GSE10072 and GSE19804) [25,34], and control lungs (GEO data
set GSE10072 and GSE19804) [25,34] (Figure 1A). The
transcript levels of 18 PLA2 family members in LAM nodule cells
were compared to non-LAM lungs (NL), respectively (Figure 1B).
Of note, two PLA2 transcripts, PLA2G16 (AdPLA2) and
PLA2G4C, were significantly higher by two-fold in LAM nodule
cells compared to control non-LAM lungs (p,0.05, Figure 1C).
Expression of AdPLA2 is upregulated in pulmonary LAM
nodules and angiomyolipomas
To validate the expression array data, the transcript levels of
AdPLA2 were examined in six LAM lungs and six control lungs
using real-time RT-PCR. LAM lungs (LAM) exhibited a twofold
increase of AdPLA2 transcript relative to control lungs (NL) (p,
0.01, Figure 2A), confirming the overexpression of AdPLA2
identified using LAM expression array analyses (Figure 1).
Moreover, immunoblotting analysis showed that LAM lungs
positive for Phospho-S6 (S235/236) accumulated higher levels of
AdPLA2 protein relative to control normal lungs (NL) (Fig-
ure 2B). Furthermore, immunohistochemical staining of two
LAM specimens showed abundant accumulation of AdPLA2 in
smooth muscle-like cells (Figure 2C). In addition, confocal
microscopy showed that smooth muscle actin-positive cells were
stained with AdPLA2, whereas pulmonary artery cells were
negative with AdPLA2 staining (Figure 2C).
Serum levels of VEGF-D have been used a biomarker for LAM
[35,36]. We recently reported that serum levels of PGE2 were
higher in women with LAM relative to healthy women [20]. To
determine the correlation of the levels of VEGF-D and PGE2 in
LAM, we collected sera from 11 LAM patients (Table 1) and
measured the levels of PGE2 and VEGF-D using ELISA. Serum
levels of PGE2 segregated into two groups: 5–10 pg/mL (high-
PGE2) and 10–20 pg/mL (low PGE2, Figure 2D). Interestingly,
serum levels of VEGF-D were lower in LAM subjects (VEGF-D
19376520 pg/mL) with lesser PGE2 compared to LAM subjects
(VEGF-D 729862529 pg/mL) with higher PGE2, indicative of a
strong correlation between PGE2 and VEGF-D (p,0.05,
Figure 2E). These data suggest that serum PGE2 could be useful
as a diagnostic marker and for assessment of disease severity.
TSC2 negatively regulates AdPLA2 expression in a
rapamycin-insensitive manner in vitro
To define the molecular mechanisms responsible for AdPLA2
upregulation in LAM, we first tested whether TSC2 plays a role in
regulating AdPLA2 expression. AdPLA2 expression was higher by
3.5-fold in TSC2-deficient LAM patient-derived cells (TSC22)
compared with TSC2-addback cells (TSC2+)( p ,0.001, Fig-
ure 3A). Because PLA2 catalyzes the conversion of plasma
membrane phospholipids to prostaglandins, we next measured
the production of PGE2 in cells lacking TSC2. TSC2-deficient
LAM patient-derived cells secreted ,75% higher levels of PGE2
compared with TSC2-addback cells (p,0.01, Figure 3B), indic-
ative of active AdPLA2.
To determine whether mTORC1 mediates AdPLA2 upregula-
tion, rapamycin treatment was employed in Tsc2
2/2p53
2/2 and
Tsc2
+/+p53
2/2 MEFs [33], Tsc2-deficient [32,37] and TSC2-
addback [38] rat uterine-leiomyoma-derived ELT3 cells, and
TSC2-deficient LAM patient-derived cells [29]. Rapamycin
treatment drastically reduced phosphorylation of S6, but had no
effect on AdPLA2 or S6 expression in Tsc2
2/2p53
2/2 MEFs
(Figure 3C). We also found that the secreted levels of 6-keto
PGF1a, a prostaglandin metabolite, were elevated by 50% in
Tsc2
2/2p53
2/2 MEFs relative to Tsc2
+/+p53
2/2 MEFs (p,
0.05, Figure 3D). Moreover, rapamycin treatment did not affect
the levels of 6-keto PGF1a (Figure 3D). Furthermore, in rat-
derived cells, the protein levels of AdPLA2 were higher in Tsc2-
deficient ELT3 cells (Tsc22) compared with TSC2-reexpressing
cells (TSC2+)( Figure 3E). Rapamycin treatment also did not
alter AdPAL2 expression (Figure 3E). Similarly, secreted levels of
PGE2 were also elevated in by ,67% in Tsc2-deficient cells
(ELT3-V3, Tsc22) relative to TSC2-reexpressing cells (ELT3-T3,
TSC2+)( p ,0.05, Figure 3F).
Since rapamycin is an allosteric partial inhibitor of mTORC1
only [39], we also examined the effects of Torin1, a potent ATP-
competitive mTORC1 and mTORC2 inhibitor [40] on AdPLA2
expression. Torin 1 reduced levels of P-Erk1/2 (T202/Y204) and
P-Akt (S473), but did not affect AdPLA2 expression in LAM
patient-derived cells (Figure 3G). Furthermore, neither Akt
inhibition (PI-103) nor MEK1/2 inhibition (PD98059) affected
AdPLA2 expression (Figure 3G). Together, our data suggest that
upregulation of AdPLA2 expression is independent of mTOR, Akt
and MEK1/2 signaling pathways in cells lacking TSC2.
TSC2 negatively regulates AdPLA2 expression in vivo
To determine whether TSC2 regulates AdPLA2 expression
in vivo, we first used xenograft tumors from mice inoculated with
TSC2-deficient ELT3-V3 (TSC22) cells and TSC2-reexpressing
ELT3-T3 (TSC2+) cells. AdPLA2 protein levels were markedly
higher by 3.5-fold in TSC2- xenograft tumors with increased
immunofluorescent staining of smooth muscle actin (a-actin), phospho-S6 (P-S6) (S235/236) and AdPLA2 in pulmonary LAM nodules from two LAM
subjects (LAM-1 and LAM-2). (D) Serum levels of VEGF-D and PGE2 were measured using ELISA from 11 clinical LAM patients. (E) The correlation of
serum levels of PGE2 and VEGF-D was analyzed. *P,0.05, ***P,0.005, Student’s t-test.
doi:10.1371/journal.pone.0104809.g002
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Mice bearing xenograft tumors of ELT3-V3 (TSC22) produced
higher urinary levels of PGE2 compared with mice bearing ELT3-
T3 (TSC2+) xenograft tumors (p,0.05, Figure 4B). The fact that
LAM is a female predominant disease made us hypothesize that
estradiol plays an important role in disease progression. To assess
the impact of estradiol on AdPLA2 expression in vivo, ovariec-
tomized female scid mice inoculated with Tsc2-deficient ELT3
cells were treated with estradiol or placebo. Xenograft tumors
were developed, as expected. The accumulation of AdPLA2 in
xenograft tumor was markedly elevated in mice receiving estradiol
compared with placebo treatment (Figure 4C). Importantly,
AdPLA2 accumulation was evident in lung metastatic lesions of
ELT3 cells in mice treated with estradiol compared with placebo
treatment (Figure 4C). These data suggest that estradiol-
enhanced AdPLA2 expression was correlated with xenograft
tumor growth and lung metastasis of Tsc2-deficient cells.
We next examined spontaneously arising renal cystadenomas in
Tsc2
+/2 mice [33]. Renal Tumors exhibited increased expression
of AdPLA2 relative to stromal cells, although some normal kidney
tubule cells were moderately positive for AdPLA2, while glomeruli
were negative for AdPLA2 (Figure 4D). We recently reported
that TSC2 negative regulates cyclooxygenase-2 (COX-2) and
prostaglandin biosynthesis [10]. To examine the impact of COX-2
inhibition on the upstream regulator, AdPLA2, Tsc2
+/2 mice
were subjected to short-term treatment with COX-2 specific
inhibitor-Celecoxib or vehicle control before harvesting renal
tumors for immunoblotting. The levels of AdPLA2 expression
from a Tsc2
+/2 mouse treated with Celecoxib remained high in
renal tumors compared to adjacent normal kidney tissues
(Figure 4D), suggesting that COX-2 targeted therapy does not
have a feedback effect on AdPLA2 expression.
Pharmacological inhibition of PLA2 selectively
suppresses the growth of TSC2-deficient LAM patient-
derived cells
To determine whether elevated PGE2 production has any
biologic consequence, we examined the cell growth in response to
PGE2 and PGI2 stimulation. PGE2 or PGI2 stimulation for 72 hr
led to a 60% or 55% increase of the growth of TSC2-deficient cells
compared with vehicle control, respectively (p,0.01, Figure 5A),
although the growth of TSC2-addback cells was not sensitive to
PGE2 or PGI2 stimulation (Figure 5A). Because mTORC1
inhibition had no effect on AdPLA2 expression, we examined
whether the PLA2 inhibitor, methyl arachidonyl fluoropho-
sphonate (MAFP), a selective, active-site directed, irreversible
inhibitor of PLA2 [41], had an effect on the growth of TSC2-
deficient cells. Treatment with 3 mM MAFP significantly reduced
the number of TSC2-deficient cells compared to vehicle control
(p,0.05, Figure 5B). Importantly, TSC2-addback cells were
resistant to 3 mM MAFP treatment, although 4.5 mM MAFP
reduced cell numbers by 80% relative to vehicle control
(Figure 5B). To further define the optimal dose of MAFP in
promoting cell death, we treated TSC2-deficient cells with 1, 2, 3,
4, and 5 mM MAFP, and TSC2-reexpressing cells with 2, 4, 6, 8,
and 10 mM MAFP. 3 mM MAFP markedly reduced cell variability
in TSC2-deficient LAM patient-derived cells (p,0.05, Fig-
ure 5C). In contrast, 8 mM MAFP decreased the variability of
TSC2-addback cells compared with vehicle control (Figure 5C).
Our data indicate that MAFP selectively suppresses the growth of
TSC2-deficient cells relative to TSC2-addback cells. Moreover,
2 mM MAFP treatments led to an increased caspase 3 cleavage,
and 5 mM MAFP caused higher levels of cleaved caspase 3 and
PARP compared with control treatment (Figure 5D). Together,
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PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e104809Figure 3. TSC2 negatively regulates AdPLA2 expression in rapamycin-insensitive manner in vitro. (A) Immunoblotting analysis of
AdPLA2 and tuberin in TSC2-deficient (TSC22) and TSCS2-addback (TSC2+) LAM patient-derived cells. Data show the mean of three sets of
independent samples. Densitometry analysis of the protein levels of AdPLA2. (B) Secreted levels of prostaglandin E2 (PGE2) were quantified in
conditioned media collected from TSC2-deficient (TSC22) and TSC2-addback (TSC2+) LAM patient-derived cells using ELISA. Results are
representative of three sets of independent samples per group. (C) Tsc2
2/2p53
2/2 and Tsc2
+/+p53
2/2MEFs were treated with 20 nM rapamycin for
24 hr. Levels of AdPLA2, tuberin and phospho-S6 (S235/236) were assessed by immunoblotting analysis. Results are representative of three different
experiments. (D) Tsc2
2/2p53
2/2 and Tsc2
+/+p53
2/2 MEFs were treated with 20 nM rapamycin (Rapa) or control for 24 hr. Secreted levels of 6-keto-
AdPLA2 as a Therapeutic Target in TSC and LAM
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e104809PGF1a were quantified in conditioned media using ELISA. Results are representative of three sets of independent samples per group. (E) Rat-derived
ELT3 cells were treated with 20 nM rapamycin (Rapa) or control for 24 hr. Immunoblotting analysis of AdPLA2 and tuberin were assessed. Results are
representative of three different experiments. (F) Secreted levels of prostaglandin E2 (PGE2) were quantified in conditioned media collected from
TSC2-deficient (TSC22) and TSC2-addback (TSC2+) ELT3 cells using ELISA. Results are representative of three sets of independent samples per group.
(G) Patient-derived TSC2-deficient (TSC22) cells were treated with 20 nM rapamycin (Rapa), 100 nM Torin1, 50 mM PI-103, 50 mM PD98059 or control
for 24 hr. Levels of AdPLA2, tuberin, phospho-Akt (S473) and phospho-Erk (T202/Y204) were assessed by immunoblotting analysis. *P,0.05, **P,
0.01, Student’s t-test.
doi:10.1371/journal.pone.0104809.g003
Figure 4. TSC2 negatively regulates AdPLA2 expression in vivo. Female CB17-scid mice were subcutaneously inoculated with ELT3-V3 cells
(TSC2-, vector) or ELT3-T3 (TSC2+, TSC2 addback) cells (n=8 mice/group). (A) Immunoblotting analysis of AdPLA2 and phospho-S6 (S235/236) in
xenograft tumors of ELT3 cells. A densitometry analysis of AdPLA2 was performed. (B) Urinary levels of PGE2 were quantified using ELISA and
normalized to creatinine levels in mice bearing xenograft tumors. Results are representative of five to nine mice per group. C) Immunohistochemical
staining of AdPLA2 in xenograft tumors of Tsc2-deficient rat-derived ELT3 cells and lungs of mice treated with placebo or estrogen. Arrowheads point
to lung metastatic lesions in estradiol-treated mice bearing xenograft tumors of ELT3 cells. (D) Tsc2
+/2 mice were treated with either vehicle or
Celecoxib (Pfizer) (0.1% in mouse chow) for one month, and then sacrificed for analysis at the end of treatment (n=3 mice/group).
Immunohistochemical staining of AdPLA2 in renal cystadenomas from Tsc2
+/2mice was performed. *P,0.05, **P,0.01, Student’s t-test.
doi:10.1371/journal.pone.0104809.g004
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the survival of TSC2-deficient LAM patient-derived cells.
Discussion
Recently we reported that COX-2 and prostaglandin biosyn-
thesis pathway is aberrantly activated in TSC2-deficient cells [10].
PGE2 and PGI2, in particular, two major prostaglandin metab-
olites of the eicosanoid end-products from the COX-2 mediated
branch of the arachidonate pathway, were significantly elevated in
TSC2-deficient cells, in preclinical models of TSC/LAM, and in
sera from women with LAM [10]. Importantly, pharmacological
inhibition of COX-2 led to apoptosis of TSC2-deficient cells, and
blocked the progression of Tsc2-deficient xenograft tumors and
kidney cystadenomas in preclinical models [10]. The findings of
elevated COX-2 activity and prostaglandin production in our
recently published study [10] led us hypothesize that phospholi-
pase A2 (PLA2), the first rate-limiting enzyme responsible for the
conversion of plasma membrane phospholipids to arachidonate
[42], is activated in cells lacking TSC2 and/or with mTORC1
hyperactivation.
Phospholipase A2s (PLA2s) belongs to a superfamily of 15
distinct members comprising four major clusters, including the
secreted sPLA2, cytosolic cPLA2, calcium-independent iPLA2,
and platelet activating factor (PAF) acetyl hydrolase/oxidized lipid
lipoprotein associated (LP) PLA2 [43–45]. Each type of PLA2
Figure 5. Inhibition of AdPLA2 selectively suppresses the growth of LAM patient-derived cells. (A) TSC2-deficient (TSC22) and TSCS2-
addback (TSC2+) LAM patient-derived cells were treated with 100 nM PGE2, 100 nM PGI2, or vehicle control for 72 hr. Cell proliferation was measured
using MTT assay. Results are representative of the average of twelve sets of independent samples per group. (B) TSC2-deficient (TSC22) and TSC2-
addback (TSC2+) LAM patient-derived cells were treated with PLA2 inhibitor methyl arachidonyl fluorophosphonate (MAFP) for 48 hr. Cell growth
was measured using MTT assay. Results are average of twelve sets of independent samples per group. (C) TSC2-deficient (TSC22) and TSCS2-addback
(TSC2+) LAM patient-derived cells were treated with PLA2 inhibitor MAFP for 24 hr. Cell proliferation was measured using crystal violet staining.
Results are representative of three sets of independent experiments. (D) LAM patient-derived TSC2-deficient (TSC22) cells were treated with MAFP at
various concentrations for 24 hr. Levels of AdPLA2, cleaved-caspase 3 and cleaved-PARP was assessed by immunoblotting analysis. Results are
representative of three different experiments. **P,0.01, Student’s t-test.
doi:10.1371/journal.pone.0104809.g005
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To determine which PLA2(s) plays a critical role in TSC/LAM
pathogenesis, we analyzed the publicly available expression array
data sets from laser capture microdissected LAM nodule cells [27]
and non-LAM lung data sets [25,26]. Surprisingly, we found that
the adipocyte-specific PLA2 (AdPLA2, also called PLA2G16) was
upregulated in LAM nodule cells relative to non-LAM lungs
(Figure 1). AdPLA2 is a major PLA2 enzyme in adipose tissue and
regulates lipolysis through PGE2 [46,47]. This finding is of
particular interest because of the ‘‘mesenchymal’’ features of
LAM, including the expression of smooth muscle actin [48] and
melanocytic markers HMB45 [49] and/or gp100 [50], the
metastatic potential [51], and epithelial-mesenchymal transition
[26]. Pathologically, renal angiomyolipomas are composed of
immature smooth muscle cells, aberrant blood vessels, and fat cells
[52]. Fat cells are also evident in a primary cultures derived from a
LAM-associated angiomyolipoma [29]. Thus, the identification of
AdPLA2 is in agreement with the characteristics of LAM patient-
derived cells.
Our current study demonstrated that the expression of AdPLA2
is negatively regulated by TSC2. However, the elevated AdPAL2
expression was not affected by pathway blockade, including
mTORC1 inhibitor rapamycin, mTORC1/2 inhibitor Torin 1,
Akt inhibitor PI-103, or MEK1/2 inhibitor PD98059, which
represents uncovered regulatory mechanisms. Several precedent
studies have documented possible mTORC1-independent cellular
outcomes in cells lacking TSC1 or TSC2 (reviewed in Neuman et
al. [53]). B-Raf kinase activity is reduced in TSC2-deficient cells
due to Rheb-GTP, but independent of mTORC1 [17,18]. Akt
activation in Tsc2
2/2p53
2/2 MEFs was reduced due to impaired
mTORC2 activity [54]. Tsc1
2/2 or Tsc2
2/2p53
2/2 MEFs had
more abundant cilia relative to the counterpart controls, and
rapamycin treatment had no effect on the cilia formation [19]. We
had previously found that the overexpression of matrix metallo-
proteinase (MMP) in TSC2-deficient LAM patient-derived cells is
insensitive to rapamycin [30]. Recently, we discovered that TSC2
negatively regulates COX-2 expression and prostaglandin pro-
duction in a rapamycin-insensitive but mTORC2-dependent
manner [10]. The current study adds to the accumulating
evidence that mTORC1-independent regulation of signaling
pathways may contribute to the pathogenesis and progression of
TSC/LAM.
The Multicenter International LAM Efficacy of Sirolimus Trial
(The MILES trial) demonstrated that the mTORC1 inhibitor
Sirolimus stabilizes lung function and improves quality of life in
LAM patients. However, upon drug discontinuation, lung function
decline resumed [15], indicating that mTORC1 inhibitor has a
cytostatic but not cytotoxic effect on LAM cells. There is an unmet
need for novel strategies to promote cell death in TSC/LAM. In
summary, we report that AdPLA2 expression is elevated in TSC2-
deficient patient-derived cells compared to TSC2-addback cells,
and that the PLA2 inhibitor selectively suppresses the proliferation
of TSC2-deficient cells. We anticipate that PLA2 inhibitors may
provide a novel therapeutic strategy for TSC and LAM.
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